A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti- epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and ...
Waterfall plot of maximum changes in SULpeak for (A) PERCIST5, (B) PERCIST1, and (C) imPERCIST5. Upper short, dashed line indicates separation of progressive metabolic disease from stable metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback